Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.9
4.9
Journals
Pharmaceutics
Special Issues
Advances in the Pharmaceutical Treatment of Cardiovascular Disease
share announcement

Advances in the Pharmaceutical Treatment of Cardiovascular Disease

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Clinical Pharmaceutics".

Deadline for manuscript submissions: 10 January 2025 | Viewed by 4090

Special Issue Editors

Dr. Magdalena Cuciureanu

E-Mail Website
Guest Editor
Department of Pharmacology, Faculty of Pharmacy, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania
Interests: clinical pharmacology; hypertension; cardiovascular diseases; lipid metabolism; nutrition
Dr. Nina Filip

E-Mail Website
Guest Editor
Department of Biochemistry, Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania
Interests: endothelial dysfunction mechanisms; cardiovascular diseases; oxidative stress; biomarkers; homocysteine; anticoagulants
Dr. Cristina-Elena Iancu

E-Mail Website
Guest Editor
Department of Biochemistry, Faculty of Pharmacy, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania
Interests: cardiovascular diseases; antioxidants; polyphenols; drugs; nanoparticles

Special Issue Information

Dear Colleagues,

It is important to note that while cardiovascular disease is a significant health problem worldwide, many cases can be prevented or effectively managed with the right lifestyle choices and medical interventions. Regular check-ups and discussions with health professionals are crucial for the early detection, prevention, and treatment of cardiovascular disease. Preventive measures for cardiovascular disease include adopting a healthy lifestyle with a balanced diet and regular exercise, avoiding tobacco and excessive alcohol consumption, and managing underlying medical conditions such as high blood pressure and diabetes. Treatment may involve lifestyle changes, medication, and, in severe cases, surgical interventions. It is widely acknowledged that the latest progress in pharmaceutics has enabled the creation of novel medications targeting cardiovascular illnesses. These advancements have the potential to markedly enhance both immediate and extended prognoses, as well as avert untimely fatalities. Consequently, we cordially invite you to submit your original articles and/or review papers to this Special Issue, whose primary objective is to highlight the advances made in contemporary pharmaceutics for cardiovascular diseases over the past few years.

In this Special Issue, entitled “Advances in the Pharmaceutical Treatment of Cardiovascular Disease”, research areas will include, but are not limited to, the following: drug delivery systems, targeted therapy for cardiovascular treatment, potential biomarkers in cardiovascular disease, drug design, drug–drug interaction, and mechanism studies.

We look forward to receiving your contributions.

Dr. Magdalena Cuciureanu
Dr. Nina Filip
Dr. Cristina-Elena Iancu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • targeted therapy
  • biomarkers
  • cardiovascular diseases
  • hypertension
  • nanotechnology
  • stem cells
  • treatment modality
  • drugs

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

13 pages, 1113 KiB  
Article
The Impact of Chronic Oral Beta-Blocker Intake on Intravenous Bolus Landiolol Response in Hospitalized Intensive Care Patients with Sudden-Onset Supraventricular Tachycardia—A Post Hoc Analysis of a Cross-Sectional Trial
by Felix Eibensteiner, Emmilie Mosor, Daniel Tihanyi, Sonja Anders, Andrea Kornfehl, Marco Neymayer, Julia Oppenauer, Christoph Veigl, Valentin Al Jalali, Hans Domanovits, Patrick Sulzgruber and Sebastian Schnaubelt
Pharmaceutics 2024, 16(6), 839; https://doi.org/10.3390/pharmaceutics16060839 - 20 Jun 2024
Viewed by 777
Abstract
Background: Landiolol, a highly cardioselective agent with a short half-life (2.4–4 min), is commonly used as a perfusor or bolus application to treat tachycardic arrhythmia. Some small studies suggest that prior oral β-blocker use results in a less effective response to intravenous β-blockers. [...] Read more.
Background: Landiolol, a highly cardioselective agent with a short half-life (2.4–4 min), is commonly used as a perfusor or bolus application to treat tachycardic arrhythmia. Some small studies suggest that prior oral β-blocker use results in a less effective response to intravenous β-blockers. Methods: This study investigated whether prior chronic oral β-blocker (Lβ) or no prior chronic oral β-blocker (L–) intake influences the response to intravenous push-dose Landiolol in intensive care patients with acute tachycardic arrhythmia. Results: The effects in 30 patients (67 [55–72] years) were analyzed, 10 (33.3%) with and 20 (66.7%) without prior oral β-blocker therapy. Arrhythmias were diagnosed as tachycardic atrial fibrillation in 14 patients and regular, non-fluid-dependent, supraventricular tachycardia in 16 cases. Successful heart rate control (Lβ 4 vs. L– 7, p = 1.00) and rhythm control (Lβ 3 vs. L– 6, p = 1.00) did not significantly differ between the two groups. Both groups showed a significant decrease in heart rate when comparing before and after the bolus administration, without significant differences between the two groups (Lβ −26/min vs. L– −33/min, p = 0.528). Oral β-blocker therapy also did not influence the change in mean arterial blood pressure after Landiolol bolus administration (Lβ −5 mmHg vs. L– −4 mmHg, p = 0.761). Conclusions: A prior chronic intake of β-blockers neither affected the effectiveness of push-dose Landiolol in heart rate or rhythm control nor impacted the difference in heart rate or mean arterial blood pressure before and after the Landiolol boli. Full article
(This article belongs to the Special Issue Advances in the Pharmaceutical Treatment of Cardiovascular Disease)
►▼ Show Figures

Figure 1

Review

Jump to: Research

16 pages, 991 KiB  
Review
An Overview of the Pharmacokinetics and Pharmacodynamics of Landiolol (an Ultra-Short Acting β1 Selective Antagonist) in Atrial Fibrillation
by Mariana Floria, Alexandru Florinel Oancea, Paula Cristina Morariu, Alexandru Burlacu, Diana Elena Iov, Cristina Petronela Chiriac, Genoveva Livia Baroi, Celina Silvia Stafie, Magdalena Cuciureanu, Viorel Scripcariu and Daniela Maria Tanase
Pharmaceutics 2024, 16(4), 517; https://doi.org/10.3390/pharmaceutics16040517 - 8 Apr 2024
Cited by 1 | Viewed by 1669
Abstract
Landiolol is an ultra-short-acting, selective β1-adrenergic receptor blocker that was originally approved in Japan for the treatment of intraoperative tachyarrhythmias. It has gained attention for its use in the management of tachyarrhythmias and perioperative tachycardia, especially atrial fibrillation for both cardiac and non-cardiac [...] Read more.
Landiolol is an ultra-short-acting, selective β1-adrenergic receptor blocker that was originally approved in Japan for the treatment of intraoperative tachyarrhythmias. It has gained attention for its use in the management of tachyarrhythmias and perioperative tachycardia, especially atrial fibrillation for both cardiac and non-cardiac surgeries. It can be the ideal agent for heart rate control due to its high β1-selectivity, potent negative chronotropic effect, a limited negative inotropic potential, and an ultrashort elimination half-life (around 4 min); moreover, it may have a potential therapeutic effects for sepsis and pediatric patients. Landiolol seems to be superior to other short-acting and selective beta-blockers such as esmolol. This review aims to provide a comprehensive overview of landiolol, a new ultra-short-acting β1 selective antagonist, including its pharmacology, clinical applications, efficacy, safety profile, and future directions in research and clinical data. Full article
(This article belongs to the Special Issue Advances in the Pharmaceutical Treatment of Cardiovascular Disease)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop